Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Phase 1b, Single-Blind, Placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate Safety and Pharmacokinetics of GS-0415 in People With HIV-1 Who Are Virologically Suppressed on Antiretroviral Treatment

NCT07719491 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT07719491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07719491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Phase 1b, Single-Blind, Placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate Safety and Pharmacokinetics of GS-0415 in People With HIV-1 Who Are Virologically Suppressed on Antiretroviral Treatment
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Recruiting
Start date
July 22, 2026
Completion date
August 31, 2029
Enrollment
112 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hiv -1 infection